BIOME 2017 Annual Conference Keynote Speaker Mike Bonney becomes CEO of Kaleido Biosciences
Kaleido Biosciences, a clinical-stage biotechnology company in Bedford, Mass developing novel chemistries to unlock the power of the human microbiome, announced the appointment of biopharmaceutical veteran
Mike Bonney
as chief executive officer and board chair of Kaleido. The Company also announced the completion of an additional capital raise, for a total of
$65 million
in funds raised to date.
|